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Abstract
Background: The leukocyte common antigen related receptor (LAR) protein has been shown to
modulate the signal transduction of a number of different growth factors, including insulin and
insulin-like growth factor 1. Splice variants exhibit differing roles and are expressed according to
tissue type and developmental stage.
Results: Using 5'RACE, we identified a 5'UTR within intron 11 of the rat LAR gene. We
demonstrated that this gives rise to a novel isoform of the LAR transcript encoded from the
identified region within intron 11. By priming across the site from exon 11 to exon 15 we show
that the novel 5'UTR is not represented in the full-length transcript and thus, it produces a
truncated form of the LAR mRNA. We examined the tissue distribution of this novel isoform and
found it to be exclusively expressed in liver. We additionally identified a liver specific 150 kDa band
with western blotting which we propose may represent the protein product of the novel transcript.
Luciferase assays showed the region immediately upstream of the 5'UTR to possesses considerable
promoter activity and that this may be conferred by the presence of a number of putative binding
sites for liver enriched transcription factors.
Conclusion: In summary, we describe a novel, liver specific, truncated isoform of the LAR
transcript transcribed under the control of an intronic promoter, potentially representing a
previously unidentified modulator of hepatic insulin signalling.
Background
The leukocyte common antigen related receptor (LAR) is
a receptor protein tyrosine phosphatase which has been
identified as a modulator of insulin and insulin-like
growth factor 1 (IGF1) signal transduction. In addition, it
has been widely studied as a key component of neural
development. The LAR protein contains 3 immunoglobu-
lin-like (Ig) and 8 fibronectin type III-like (FN) domains
extracellularly, a transmembrane domain (TM) and 2
intracellular phosphatase domains (PTP-1 and PTP-2).
The extracellular domains mediate cell-cell and cell-extra-
cellular matrix (ECM) interactions. Modulation of signal
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which is conferred by the first phosphatase domain [1,2].
The second is important for substrate recognition.
The expression of up to 32 different isoforms of the LAR
transcript have been postulated to result from 5 separate
splicing variations [3] within the fibronectin-like domains,
proximal to the transmembrane domain and at the 3' end
of the transcript. Different isoforms of the LAR transcript
have been shown to be differentially expressed across a
wide range of tissues [3], during different stages of neural
development [4] and a specific isoform containing a dis-
tinct ectodomain in the fifth FNIII domain has been found
to be important in the promotion of neurite outgrowth [5].
The LAR induced modulation of neural growth appears to
be mediated by its interaction with the nerve growth fac-
tor (NGF) [6] and brain derived neurotrophic factor
(BDNF) [7] signalling pathways, whilst its influence on
the insulin signalling pathway may play a significant role
in glucose homeostasis. This variety of functions across
different tissue types suggests either a commonality of
structural interaction, or a tissue specific variation in iso-
form expression.
Through modulation of the insulin signalling pathway
the LAR protein has been shown to promote an insulin
resistant phenotype. The LAR protein physically interacts
with the insulin receptor (IR) [8] and promotes its de-
phosphorylation [9,10] via its cytoplasmic domains [11].
Direct interaction between the LAR protein and IR was
seen to be increased with insulin treatment [8]. Antisense
knockdown of LAR transcript in vitro leads to a marked
elevation of IR autophosphorylation and insulin depend-
ent phosphatidylinositol 3-kinase (PI3K) activity [12-14],
whilst Chinese hamster ovary (CHO) cells overexpressing
LAR protein show a reduction of insulin receptor (IR) and
insulin receptor 1 (IRS1) phosphorylation [10].
Here we identify a novel, liver specific isoform of the rat
LAR transcript encoded from a 5'UTR located within
intron 11 of the full-length gene and examine the expres-
sion of this isoform in a rat model of insulin resistance
induced by fetal exposure to a maternal dietary protein
restriction [15].
Results
5'RACE identified a novel 5'UTR within the liver expressed 
rat transcript
We carried out a 5'RACE analysis of the LAR transcript,
priming from within exon 15. This identified a unique
transcript including 165 bp of intron 11 located 805 bp
upstream of exon 12 and 3056 bp downstream of exon
11, in addition to exons 12–15 (Figure 1). The identified
region was also located 341 bp downstream of a previ-
ously described LAR alternatively spliced element (LASEc;
[3]). BLAST analysis of this region against mouse and
human sequences failed to show the presence of any un-
annotated exons, demonstrating that we had identified
either, a novel 5'UTR for a truncated transcript coding
from this region or an unidentified exon.
A shortened transcript is encoded from the new 5'UTR
In order to confirm the presence of this putative 5'UTR
within the native mRNA, we carried out PCR analysis of
cDNA derived from rat liver. Primers were designed to rec-
ognise a region within the newly identified 5'UTR and a
region of exon 15 (Figure 2A). PCR products of 1061 bp
were expected, and bands of over 1 kb were observed (Fig-
ure 2B). Sequencing confirmed the presence of the 5'UTR
and exons 12–15 within the novel transcript, however, we
also noted the exclusive retention of intron 12 (75 bp),
thus producing a band of 1136 bp (Figure 2B). The obser-
vation of a retained intron within the PCR product which
had not been seen in the 5'RACE suggests that different
forms of this novel transcript may exist.
We chose to examine the expression of the newly identi-
fied isoform in liver tissue from animals exposed to a
maternal dietary protein restriction during gestation (Fig-
ure 2Bi) in order to determine the contribution, if any, of
the LAR gene product in the development of insulin resist-
ance in this model of metabolic programming. Beta-actin
was used as a loading control (Figure 2Biii). From gross
analysis of the PCR products, we did not see any overt dif-
ferences in expression levels of any of the products
described above, between animals exposed to maternal
undernutrition during gestation when compared with
controls. We therefore chose not to examine the expres-
sion levels in any more detail in these animals.
To demonstrate that the novel 5'UTR was exclusively part
of a transcript encoded from this point downstream,
rather than merely an additional exon of the full-length
transcript, we carried out PCR analysis of rat liver cDNA
using primers designed against exons 11 and 15 (Figure
2Bii). The expected band of 991 bp was observed with no
other bands visible, supporting the hypothesis that the
newly identified internal 5'UTR was indeed exclusively
part of a transcript encoded from this point.
The newly identified transcript is expressed exclusively in 
liver tissue
We examined expression of the LAR transcript and the
newly identified isoform in a number of rat tissues in
order to determine its distribution. cDNA was synthesised
from RNA extracted from adrenal, testis, lung, colon, liver,
brain, kidney, small intestine, spleen, skeletal muscle and
fat, from an adult male rat supplied standard laboratory
chow and tested for the presence of the newly identifiedPage 2 of 12
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exclusively confined to liver (Figure 2Ci) whilst the tran-
script identified using primers against exons 11 and 15
was observed in all tissues tested (Figure 2Cii). This fur-
ther confirmed that the newly identified 5'UTR represents
the first exon of a truncated transcript encoded from this
point as it did not appear in native transcripts which
include the upstream exon 11.
We observed strong expression of the "full-length" tran-
script (i.e. those including exon 11) in all tissues except
muscle and brain, which showed lower levels of this iso-
form. Instead, at least in brain, LAR mRNA was signifi-
cantly represented by a shortened isoform of the "full-
length" transcript. This shortened isoform was also
observed, albeit to a much lesser extent, in testis, colon
and small intestine (Figure 2Cii). Beta-actin was used to
demonstrate equivalent loading (Figure 2Ciii).
Using real-time PCR we found that the full transcript was
expressed at a level approximately 2 to 3 fold higher than
that of the truncated hepatic isoform.
In order to determine whether a protein product of the
truncated isoform might be produced, we carried out
Western blotting using two different antibodies, one
directed upstream of the region encoded by the transcript
subsequent of the 5'UTR (amino acids 24–196 of human
LAR; antibody A1; Figure 3A) and another targeted down-
stream of this site (amino acids 1250–1350 of human
LAR; antibody A2) in a panel of tissues. Probing with anti-
body A1 initially in liver and brain identified a single
band of approximately 150 kDa in both tissues, represent-
ing the processed extracellular region of the full-length
protein described previously as the E-subunit (Figure 3Bi;
[16]), in addition to two shorter bands of approximately
100 kDa and 80 kDa in brain. Probing liver and brain
using antibody A2 revealed a different pattern of bands
(Figure 3Ci -BP). In liver, we detected bands at approxi-
mately 150 kDa, 72 kDa, 70 kDa, 60 kDa and 30 kDa,
whilst in brain, we observed bands at approximately 85
kDa, 72 kDa, 70 kDa, 60 kDa and 50 kDa. The bands seen
at 85 kDa, 72 kDa and 70 kDa most likely represent the
internal processed P-subunit, the LAR c-terminal fragment
LAR-CTF and the LAR intracellular domain LICD respec-
5'RACE identification of a novel 5'UTR in intron 11 of the LAR geneFigure 1
5'RACE identification of a novel 5'UTR in intron 11 of the LAR gene. (A) Structure of the rat LAR gene. (B) Magnifi-
cation of the region of the novel 5'UTR. Open box – 5'UTR, LASEc – LAR alternatively spliced element c. Exons and alterna-
tively spliced elements are represented as boxes in all figures, labelled as follows: White dots on black background – LASEc, 
black dots on white background – exon 12, dark grey – exon 13, light grey – exon 14, wavy lines – exon 15 & diagonal dashing 
– exon 16.Page 3 of 12
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to specifically identify the LAR protein. With the exception
of the bands at ~60 kDa, all of the species described were
considerably diminished in intensity or disappeared alto-
gether when blocking peptide was incubated with the pri-
mary antibody (Figure 3Ci +BP). This additionally
suggests that these bands may well represent specific LAR
protein targets of the antibody whilst the ~60 kDa bands
may well be non-specific targets of antibody A2. It was
interesting to note two additional bands in brain tissue at
approximately 50 kDa with antibody A2. Non-specific
proteolysis is most likely to occur in brain tissue due to
the rapid rate of its degradation post-mortem, however,
the lack of further, shorter bands in brain tissue, in addi-
tion to the lack of any short bands using antibody A1,
might suggest that these two are representative of either
different brain specific isoforms, or novel processed forms
of the full-length protein. It should be noted, that these
bands also diminished significantly after incubation with
blocking peptide (Figure 3Ci +BP).
We therefore identified two apparently liver specific bands
of 150 kDa and 30 kDa using an antibody directed down-
stream of the novel transcription start site. Antibody A2,
as previously mentioned, was raised against a peptide cor-
responding to amino acids 1250–1350 of the human full-
length LAR protein (aa1241-1341 in the rat protein). The
LAR protein is processed in vivo via several cleavage
events. The 150 kD E-subunit is produced by processing at
a furin cleavage site located immediately below amino
PCR analysis of the novel transcript from a variety of rat tissuesFigure 2
PCR analysis of the novel transcript from a variety of rat tissues. (A) Primer locations to produce either (i) the novel 
transcript, (ii) the full-length transcript spanning the region of the 5'UTR, or (iii) beta-actin. These primers were used to exam-
ine the presence of the novel transcript in (B) liver from male offspring of rats supplied either a control (Control) or low pro-
tein diet (maternal low protein-MLP) during gestation and lactation and (C) a variety of normal rat tissues. A-Adrenal, T-Testis, 
Lu-Lung, C-Colon, Li-Liver, Br-Brain, K-kidney, SI-Small Intestine, Sp-Spleen, M-Muscle, F-Fat.Page 4 of 12
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comprising the region downstream of this site. The 150
kDa band identified in liver by antibody A2 therefore can-
not be the E-subunit as the furin cleavage site is upstream
of the region against which the antibody was raised and
thus may represent a unique isoform of the LAR protein.
In order to determine whether the 150 kDa and 30 kDa
isoforms were truly liver specific, we probed a wider panel
of tissues using antibody A2 (Figure 3Cii). Most tissues
examined demonstrated expression of the 72 kDa LAR-
CTF (Figure 3Cii – +) and brain tissue was again shown to
express the 85 kDa P-subunit (Figure 3Cii – *). This anti-
body identified numerous bands in different tissues, some
of which may well be a consequence of non-specific bind-
ing. However, we found that the 150 kD band (arrow-
head) is indeed liver specific, whilst the 30 kD protein
(dotted arrows) is present in liver, muscle and, at very low
levels, small intestine. We therefore suggest, that the 150
kD band identified by antibody A2 represents the likely
protein product of the liver specific transcript which we
have identified within this article. It should be noted that
the E-subunit was demonstrated to be present in all tis-
sues examined (Figure 3Biia and 3Biib – arrows) using
LAR protein expression in liver and brainFigure 3
LAR protein expression in liver and brain. (A) Full-length LAR protein structure showing the location of the IgG-like, 
FNIII-like, transmembrane and phosphatase domains. The target regions of antibodies A1 and A2 are shown. The location of 
the putative translation start site of the novel isoform encoded by the 5'UTR is also shown. (Bi) Western blot of liver (L) and 
brain (Br) tissue probed using antibody A1. (Biia) Western blot of liver (Li), small intestine (SI), kidney (K), brain (Br), testicle 
(T), heart (Ht), adrenal (A) and muscle (M) probed using antibody A1. Arrows identify the E-subunit. (Biib) A lengthened expo-
sure of the western blot shown in Biia identifying the 150 kDa E-subunit in all tissues (arrows). (Ci) Western blot of liver and 
brain probed with antibody A2 either without (-BP) or with (+BP) blocking peptide. (Cii) Western blot of liver, small intestine, 
kidney, brain, testicle, heart, adrenal and muscle using antibody A2. Arrowhead identifies a liver specific band at 150 kDa. Dot-
ted arrow identifies a band at 30 kDa. * identifies the P-subunit, + identifies the LAR-CTF.Page 5 of 12
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with antibody A2 was not simply a consequence of a cross
reaction with the E-subunit.
We have hypothesised that the methionine at position
817 of the LAR protein may represent the start of transla-
tion of the novel isoform. A protein including all down-
stream amino acids is estimated (using the BioEdit
program – http://www.mbio.ncsu.edu/BioEdit/
bioedit.html) to be approximately 123 kD in size. It
should be noted that BioEdit predicts the sequence encod-
ing the E-subunit of the full-length LAR to be approxi-
mately 129 kD in size. This would support the contention
that the 150 kDa band, does indeed represent the protein
product of the novel liver specific transcript.
The 5'UTR and the upstream region show species 
conservation
We proposed that, if this region represents a conserved
transcriptional initiation site for a shortened transcript,
then it should share sequence homology with other spe-
cies. The intronic region containing the 5'UTR was subject
to BLAST analysis against mouse and human sequences.
The regions identified (Figure 4A) were then examined
using the ClustalW sequence alignment tool and those
regions of closest homology determined.
We found an 824 bp conserved region of intronic DNA
which contained the 5'UTR and extended 582 bp
upstream encompassing the previously described LASEc,
plus an additional 212 bp 5' of LASEc in addition to 79 bp
downstream of the 5'UTR (Figure 4A&4B). This region
showed sequence homology of 95% with mouse and 82%
with human. Comparison of the sequence between LASEc
and the start of the 5'UTR showed sequence homology of
97% between rat (341 bp) and mouse (340 bp) and 88%
between rat and human (355 bp).
Comparison of the remaining portion of the upstream
intron demonstrated sequence homology of 85%
between rat and mouse and 53% between rat and human.
Downstream of the consensus region, the intronic
sequence homology between rat and mouse was 70%
whilst that between rat and human was only 56%.
For the sake of completeness, we also examined the
sequence homology between species of the upstream
exon (97% between rat and mouse, 88% between rat and
human) and the downstream exon (94% between rat and
mouse, 88% between rat and human).
The region upstream of the 5'UTR demonstrates promoter 
activity
The considerable degree of homology across species sup-
ported the hypothesis that this region represents a con-
served promoter. Furthermore, closer examination of the
promoter region revealed the presence of putative tran-
scription factor consensus binding sites which may be
important in determining its liver specific expression (Fig-
ure 4B). We identified two E-boxes, two hepatocyte
nuclear factor 4 alpha (HNF4α) binding sites, a peroxi-
some proliferator-activated receptor response element
(PPRE) and a cAMP response element (CRE). The PPRE
and the first HNF4α consensus sites overly each other,
with the PPRE on the "antisense" (-ve) strand and the
HNFα site on the "sense" (+ve). We also observed a puta-
tive glucocorticoid response element upstream of the
LASEc containing region.
We further identified a putative CAAT box 72 bp upstream
of the transcription start site (TSS) in addition to a poten-
tial TATA binding protein (TBP) binding site located 37
bp upstream of the TSS (Figure 4B).
We examined the activity of this putative promoter region
using a luciferase assay. Regions around the 5'UTR (Figure
5) were amplified, cloned into the pGL4.10 luciferase
expression vector and transfected into McArdle RH7777
cells.
Promoter constructs containing the complete region of
homology in addition to 42 bp upstream (Figure 5Biv)
demonstrated clear promoter activity in McArdle RH7777
cells. Loss of the 42 bp had no effect on promoter activity
as values from the full-length construct were identical to
those without the additional bases (P = 0.851; Figure
5Biii). The full-length construct showed an approximately
20 fold increase in promoter activity over baseline values
from pGL4.10 [luc] alone (P < 0.01). Removal of the
region containing LASEc and 75 bp downstream which
includes the first putative E-box (Figure 5Bii), halved the
activity of the promoter region (P < 0.01), but still
retained considerable activity relative to the empty vector
(approximately 10 fold higher; P < 0.01). The loss of an
additional 192 bp (inclusive of the first HNF4α/PPRE
site) almost completely abolished promoter activity (Fig-
ure 5Bi).
These data demonstrate that the 824 bp homologous
region possesses considerable promoter activity conferred
by two distinct parts. First, the region immediately
upstream of the 5'UTR and secondly, by the region con-
taining LASEc.
Discussion
In this study we have demonstrated the existence of a
novel, liver-specific transcript of the rat LAR gene. We
identified a shortened isoform coding from an intronic
region upstream of exon 12 of the LAR gene. This is pro-
duced under the control of an internal promoter region
located within intron 11 and which includes a previously
identified LAR alternatively spliced element (LASEc; [3]).Page 6 of 12
(page number not for citation purposes)
BMC Molecular Biology 2009, 10:30 http://www.biomedcentral.com/1471-2199/10/30We have shown that the region identified as a putative
internal 5'UTR is not present within PCR products pro-
duced by priming between exons 11 and 15, indicating
that this region is not contained within the full-length
transcript and therefore, that it represents the first exon of
a truncated form of the gene. Furthermore, expression of
the newly defined transcript is exclusively confined to the
liver.
A role for the LAR protein has been implicated in numer-
ous biological processes ranging from neural develop-
ment to modulation of insulin signalling [18]. Many
isoforms have been identified which are expressed specif-
ically according to both tissue type and developmental
stage. The LAR protein has been implicated in the modu-
lation of the signalling pathway of a number of growth
factors, including nerve growth factor (NGF) [6], brain
derived neurotrophic factor (BDNF) [7], insulin [8,10,12-
14] and IGF1 [19].
These studies suggest a variety of roles for the LAR protein
in the developing and postnatal individual which may be
modulated by isoform, tissue type and pathological phe-
notype. We have demonstrated that expression of the
shortened transcript is restricted to liver, with no evidence
of expression in any other adult tissue despite the appar-
ent widespread distribution of the full-length transcript.
This would suggest that the control of expression of the
newly identified isoform is under the control of liver
enriched transcription factors. In addition, the liver
restricted expression suggests a liver specific function for
this isoform. With regard to postnatal liver function, of
most relevance would be the insulin and IGF1 pathways,
we therefore hypothesise that one or both of these signal-
Location and annotation of the 824 bp homologous region surrounding the 5'UTRFigure 4
Location and annotation of the 824 bp homologous region surrounding the 5'UTR. (A) Magnified region surround-
ing the 5'UTR. (B) Rat, mouse and human sequences corresponding to this region. Thin boxes correspond to the (1) LASEc 
site and the (2) novel 5'UTR. Thick boxes correspond to putative transcription factor binding sites-GRE-Glucocorticoid 
response element, PPRE-peroxisome proliferator activated receptor response element, HNF4α-Hepatocyte nuclear factor 4 
alpha, CRE-cAMP response element. +ve = located on the sense strand; -ve = located on the antisense strand. Arrowheads 
correspond to (i) CAAT box, (ii) putative TATA box and (iii) transcription start site.Page 7 of 12
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isoform.
Overexpression of LAR protein has been shown to depress
IR and IRS1 phosphorylation in CHO cells [10] whilst
skeletal muscle specific overexpression in the mouse,
decreases glucose disposal and results in insulin resistance
[20] apparently mediated by reduced IRS2 phosphoryla-
tion and IRS induced PI3K activity. In humans, obesity
was shown to result in a significant elevation of LAR
expression in skeletal muscle [21] in association with con-
siderably impaired insulin induced glucose disposal and
enhanced phosphatase activity. Phosphatase activity was
reduced to levels seen in lean individuals only by immu-
nodepletion of LAR protein.
LAR transcript knockdown in McArdle RH7777 rat
hepatoma cells [12-14] leads to a marked elevation in IR
autophosphorylation, whilst a similar loss in HEK293
cells appears to have no effect on IR or IRS1 phosphoryla-
tion but instead, results in post-receptor insulin resistance
as evidenced by impaired Akt and MAPK phosphorylation
[22]. Loss of LAR gene product in a mouse knockout
model results in reduced fasting levels of insulin, glucose
[23] and IGF-1 [19] alongside elevation of IGF-1 stimu-
lated phosphorylation of IGF-1R, IRS1, IRS1 associated
PI3K and extracellular signal related kinase (ERK1/2)
activity in vascular smooth muscle cells. In these same
animals, absence of LAR gene product is associated with a
greatly enhanced proliferation of the neointima in
response to arterial injury. The functional role of the LAR
protein appears, therefore, highly tissue specific.
The transcription start site (TSS; Figure 4B arrowhead iii)
is preceded by two structures indicative of a classical pro-
moter, namely a CAAT box (arrowhead i) and a putative
TATA box (arrowhead ii). The CAAT box is located 73 bp
upstream of the TSS whilst the sequence TGAAAA which
may bind the TATA box binding protein (TBP) is located
in an appropriate position 37 bp upstream of the TSS. The
promoter region appears to contain consensus binding
sites for a number of transcription factors relevant to the
isoform's liver specific expression profile. Of note are two
HNF4α binding sites, a PPRE and two E-boxes. All of the
putative binding sites share good homology (100% in the
case of the E-boxes) with mouse and human (Figure 4).
Promoter activity of the region surrounding the 5'UTRFigure 5
Promoter activity of the region surrounding the 5'UTR. (A) Region around the 5'UTR used for the creation of pro-
moter constructs. (B) Promoter constructs with corresponding luciferase activity.Page 8 of 12
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reduced with the loss of the sequence containing the first
E-box (Figure 5Bii) and was further diminished with the
removal of the first HNF4α/PPRE site (Figure 5Bi). The
low level of activity of the shortest promoter construct
suggests that either the response elements identified
within this region (the second HNF4α, second E-box and
CRE) are inactive, or that their activity is driven by specific
cellular responses.
The presence of HNF4α binding sites may imply constitu-
tive expression of the shortened isoform in liver, however,
the additional E-boxes suggests the possibility of nutri-
tional control of expression, particularly if the steroid
response element binding protein 1c (SREBP1c) is found
to transactivate the promoter at either or both of these
sites. SREBP1c activity is elevated in response to glucose
and insulin signalling [24] and thus, expression control
exerted by this protein might underlie a novel feedback
loop with the insulin signalling pathway.
We examined the expression of the novel isoform of the
LAR transcript in an established model of developmen-
tally programmed adult insulin resistance [15] in order to
identify whether this specific transcript may play a role in
the development of the insulin resistant phenotype. How-
ever, we failed to observe any overt differences in expres-
sion of the newly identified shortened isoform between
males from either dietary group and thus chose not to pur-
sue this further.
In the rat, the LAR gene is encoded by 31 exons to produce
a protein possessing 3 IgG like domains, 8 FNIII-type
domains, a transmembrane domain and two intracellular
phosphatase domains (Figure 3A) [1]. The transcription
start site of the shortened isoforms described here is
located towards the end of the 5th FNIII type domain and
therefore it is predicted that the protein product of this
isoform would only possess a limited extracellular
domain. The first ATG encountered when examining the
truncated transcript actually exists at the end of the novel
5'UTR and would be in frame with the remainder of the
transcript. However, closer inspection of the homologous
region in the human sequence shows this site to be repre-
sented as ACG (Figure 4B) and therefore the rat ATG is
likely to be a consequence of a de-amination event
[25,26] in early rodent evolution (as the ATG is present in
the mouse sequence also). It is, therefore, likely that the
initiator methionine is encoded by the first of two adja-
cent ATG codons located within exon 13. This methionine
is close to the start of the FNIII-6 domain (amino acid 817
of the full-length LAR protein) as predicted by Pfam anal-
ysis of the protein sequence and thus, it is anticipated that
the protein product of this truncated isoform should pos-
sess the majority of the FNIII-6 domain in addition to an
unknown portion or portions of the protein downstream
of this site. Examination of the region around the pre-
dicted initiator methionine (CCACCATGA) shows tight
homology with the classical Kozak sequence (CCA/
GCCATGG/A; [27,28]). The +4 position relative to the
start of the ATG is most commonly represented by a G,
however the next most frequent occurrence is an A resi-
due. This, alongside the presence of an A in the -3 posi-
tion, supports the assertion that the transcript encoded
downstream of the novel 5'UTR is translated.
Importantly, we identified a liver specific band with West-
ern blotting of approximately 150 kDa which we propose
may represent the translated product of this truncated
transcript. If, as we have suggested, translation begins with
the methionine at position 817, then this would result in
the production of a protein which included part of the
FNIII 6 domain in addition to domains FNIII 7 & 8, as
well as the transmembrane domain and both phos-
phatase domains. Thus, such a protein should retain the
capacity to de-phosphorylate target proteins. Examination
of the region immediately downstream of this methionine
for the presence of a signal peptide using the SignalP 3.0
server http://www.cbs.dtu.dk/services/SignalP/[29,30]
failed to identify a signal sequence, possibly suggesting
that the protein may not be secreted and retained within
the cytoplasm, but this does not preclude its capacity to be
trafficked to the plasma membrane. The truncation of the
extracellular domain may influence the control of activity
of this novel isoform as homophilic binding to extracellu-
lar regions (FNIII 3) with an ectodomain isoform or a
peptide mimetic of this isoform directly influences LAR
phosphatase activity during neural development [5,31].
The modification of the extracellular domain of this iso-
form may therefore influence LAR protein activity in a dif-
ferent manner to that of the full-length protein.
Interestingly, the 5th FNIII domain appears to be impor-
tant in the mediation of LAR protein function. A short
ectodomain isoform of the LAR protein containing a
novel shortened amino terminus in addition to the FNIII-
5 domain (LARFN5C) was shown to act as a direct ligand
of the LAR protein and enable neurite outgrowth [31] as
was a peptide mimetic complementary to this region [5].
It has been suggested that the activity of receptor protein
tyrosine phosphatases (rPTP) is regulated by homophilic
interactions [32], with monomeric rPTPs being constitu-
tively active and dimerization leading to inactivation.
Thus, it was proposed that the activity of the LAR protein
induced by binding of the LARFN5C isoform or mimetic
peptide, might be mediated by preventing inactivation
through homophilic binding. It is noteworthy that LAR
protein activity induced by ECM interactions, in particular
with the laminin-nidogen complex, appears similarly to
be mediated via the FNIII-5 domain [33]. It remains to bePage 9 of 12
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protein product is, in addition to the protein function and
whether this is exerted intra- or extracellularly.
In summary, we have identified a novel isoform of the
LAR transcript which is encoded from a region within
intron 11 and is exclusively expressed in liver. This iso-
form is under the control of a promoter located upstream
of the newly identified 5'UTR. Future work will aim to
understand the functional significance of hepatic expres-
sion of this new truncated isoform, in particular in rela-
tion to insulin signal transduction, in addition to the
control of its expression.
Conclusion
The LAR gene product is expressed in a number of iso-
forms and this is dependent upon tissue type. It would
appear that the functional role of the LAR protein may be
principally determined by the isoform expressed and in
particular, by the structure of the region around the FNIII
domains 4–7. Thus it may be suggested that tissue specific
function is conferred by the nature of the extracellular
region of the LAR protein. We have identified a novel
truncated isoform of the LAR transcript which we have
further demonstrated to be liver specific and which is
expressed under the control of a promoter region possess-
ing consensus sites for a number of liver enriched tran-
scription factors. We propose that this represents a novel
mechanism for the determination of liver specific LAR
protein function which, by virtue of the restriction of its
expression, may prove to play a significant role in the




All animal work was carried out in accordance with the
Scientific Procedures (Animals) Act 1986, UK. Female
Wistar rats (Charles River, UK) were mated and supplied
either a control diet containing 20% protein by weight
(Control) or a low protein diet containing 8% protein by
weight (MLP – Maternal Low Protein) throughout preg-
nancy and lactation. At birth, offspring were randomly
culled to 8 per litter (4 males and 4 females) and then
weaned onto identical diets at 3 weeks of age. At 4 weeks
of age, animals were fasted for 12 hours and sacrificed
using schedule 1 methods. Organs were removed and
snap frozen in liquid nitrogen and subsequently stored at
-80 C for later analysis. Up to 3 litters were used from each
dietary group.
RNA ligase-mediated rapid amplification of 5' cDNA ends
5'RACE was carried out using the Generacer Kit (Invitro-
gen, Paisley, UK). All procedures were carried out accord-
ing to the manufacturer's instructions. 5'RACE nested PCR
reactions were carried out using primer 5'1 targeted
against exon 15 (GCAGTGCGGATGGACACCAGGTGCT-
GTA) for the first round and primer 5'2 located 41 bp
upstream of primer 5'1 (GGTTCATCAGGACGAAGGAG),
for the second round. PCR generated products were
cloned using the TOPO TA cloning kit for sequencing
(Invitrogen, Paisley, UK) and sequenced (Geneservice,
Nottingham, UK).
5'RACE generated sequences were identified using the
Basic Local Alignment and Search Tool provided by
Ensembl http://www.ensembl.org/Multi/blastview.
Sequences were searched against mouse and human
genomes and regions found to be similar between the
three species were compared using ClustalW version 1.83
http://www.ebi.ac.uk/Tools/clustalw/index.html.
Promoter constructs
Regions surrounding the newly identified 5'UTR were
amplified from template DNA produced by PCR using
primers upstream (GCTGAGAGCAGGATGGGTAG) and
downstream (CACTGATGCCCAAGAAGTCA) of the site
of interest (1039 bp). Constructs were produced using
primers designed to insert an XhoI consensus site 5' and
an EcoRV site 3' of the DNA product for subsequent diges-
tion. Constructs were produced in order to enable the
determination of promoter activity of the entire homolo-
gous region upstream of the newly identified 5'UTR.
Therefore a reverse primer, directed against the sequence
80 bp downstream of the new 5'UTR (ATATGGATATCTT-
TCCGGACATGCGGAGAAA), was used in PCR against
four different forward primers. The forward primers used
produced constructs of 318 bp (ATATTCTCGAGTC-




respectively. All constructs and pGL4.10 [luc2] expression
vector were cut first with EcoRV (Promega, Southampton,
UK) and second with XhoI (Promega, Southampton, UK)
restriction endonucleases according to manufacturers
guidelines. DNA constructs were then ligated into
digested pGL4.10 [luc] using T4 DNA ligase (NEB,
Hitchin, UK) according to manufacturers instructions.
Ligated vectors were then cloned into JM109 competent E.
Coli (Promega, Southampton, UK).
Cell culture and luciferase assay
McArdle RH7777 rat hepatoma cells were grown in
DMEM (Sigma, Poole, UK) supplemented with Penicillin/
Streptomycin (Sigma, Poole, UK), 2 mM L-Glutamine
(Sigma, Poole, UK) and 10% heat inactivated fetal bovine
serum (Gibco). Cells were plated into 24-well tissue cul-
ture plates (Falcon) at a density of approximately
100,000/well. Promoter constructs were transfected intoPage 10 of 12
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tics, West Sussex, UK) according to the manufacturers
instructions. After 48 hrs, cells were lysed using luciferase
substrate (Promega, Southampton, UK) and lysates were
analysed for luciferase activity with a microplate lumi-
nometer (Turner Designs, California, USA). All assays
were carried out in triplicate.
PCR analysis of transcripts
PCR was carried out in order to verify the presence of the
newly identified 5'UTR in native mRNA. Primer locations
are annotated in Figure 2A. One forward primer directed
against the 5'UTR (1F; TGGGAGCCAGGTCCAGTACT)
was used with a reverse primer directed against exon 15
(1R; GGTTCATCAGGACGAAGGAG) to produce a prod-
uct of 1137 bp. A forward primer directed against exon 11
(2F; ATTCGTGGCTACCAGGTCAC) was used against 1R
to demonstrate that the new 5'UTR was not incorporated
within the full-length transcript (991 bp). Primers
directed against rat β-actin were used to show equal load-
ing (251 bp; Forward – AGTACCCCATTGAACACGGC,
Reverse – AATGCCAGTGGTACGACCAGA). The relative
expression levels of the full-length transcript and novel
truncated isoform were compared using real-time PCR.
Primers were designed to detect the full transcript (138
bp; Forward – ATTCGTGGCTACCAGGTCAC, Reverse –
AATGGAGTAGGTGGTCTCGG) and the novel isoform
(135 bp; Forward – CACCTGAGGCTTAAAGCTGG,
Reverse – CCCTTAGTGGTGTAGGCAGC). Real-time PCR
was carried out in triplicate using Lightcycler 480 SYBR
Green 1 Master (Roche Diagnostics, West Sussex, UK) and
was run on a Lightcycler 480 (Roche Diagnostics, West
Sussex, UK). All PCR products were sequenced to confirm
their identity.
Western blotting
Tissues were removed and immediately disrupted in 5 vol-
umes of ice-cold homogenisation buffer (150 mM NaCl,
50 mM HEPES, 2.5 mM EDTA, 10% glycerol, 1% Triton,
1 mM Na3VO4, 10 mM NaF) containing a protease inhib-
itor cocktail (Roche Diagnostics, West Sussex, UK). Sam-
ples were homogenised on ice using a dounce
homogeniser and subsequently passed 10 times through a
21 guage needle. Samples were spun at 13000 rpm at 4°C
for 5 minutes and the supernatant removed. Protein con-
centration was determined using the Bio-Rad protein
assay system (Bio-Rad, Hemel Hempstead, UK) according
to manufacturer's instructions.
Approximately 50 μg protein was electrophoresed down a
10% polyacrylamide gel and transferred to nitrocellulose
paper for probing with antibodies directed against differ-
ent regions of the LAR protein (BD, Oxford, UK – anti-
body A1 and Abcam, Cambridge, UK – Antibody A2) Both
primary antibodies were incubated at a concentration of
1:1000 in blocking solution (5% dried skimmed milk in
tris-buffered saline with 1% Tween 20). Secondary anti-
bodies conjugated to horseradish peroxidise (Sigma,
Poole, UK; GE healthcare, Amersham, UK) were incu-
bated at a concentration of 1:5000 in blocking solution.
Bands were visualised using ECL Plus reagent (GE health-
care, Amersham, UK).
Statistical analysis
Students T-test was used.
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